Pharmaceutical News

RSS
Efficacy of monoclonal antibodies against Omicron BA.1, BA.2, and BA.5

Efficacy of monoclonal antibodies against Omicron BA.1, BA.2, and BA.5

A comparison of SARS-CoV-2 antibody profiles in elderly and younger individuals

A comparison of SARS-CoV-2 antibody profiles in elderly and younger individuals

The nose key to winning the war against COVID-19

The nose key to winning the war against COVID-19

Listen: Can California lower the price of insulin?

Listen: Can California lower the price of insulin?

Study confirms efficacy of molnupiravir against COVID in a real-life cohort

Study confirms efficacy of molnupiravir against COVID in a real-life cohort

Nasal spray highly effective against HIV and SARS-CoV-2 in animal models

Nasal spray highly effective against HIV and SARS-CoV-2 in animal models

Three doses of Novavax vaccine effective against Omicron subvariants

Three doses of Novavax vaccine effective against Omicron subvariants

Researchers report ‘hybrid immune damping’ following SARS-CoV-2 Omicron infection

Researchers report ‘hybrid immune damping’ following SARS-CoV-2 Omicron infection

A VSV-based COVID vaccine effective against SARS-CoV-2 variants

A VSV-based COVID vaccine effective against SARS-CoV-2 variants

Bivalent mRNA vaccine induces powerful antibody response to SARS-CoV-2 Omicron subvariants

Bivalent mRNA vaccine induces powerful antibody response to SARS-CoV-2 Omicron subvariants

Researchers investigate a drug used for neuromuscular weakness as potential treatment for botulism

Researchers investigate a drug used for neuromuscular weakness as potential treatment for botulism

KHN’s ‘What the Health?’: Drug price bill is a go in the Senate

KHN’s ‘What the Health?’: Drug price bill is a go in the Senate

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

High-level resistance of SARS-CoV-2 BA.4 against neutralizing antibodies

High-level resistance of SARS-CoV-2 BA.4 against neutralizing antibodies

COVID vaccines induce memory B and T cells in primary antibody deficient patients

COVID vaccines induce memory B and T cells in primary antibody deficient patients

Fourth dose of Pfizer mRNA COVID vaccine protective against variants and symptomatic infection

Fourth dose of Pfizer mRNA COVID vaccine protective against variants and symptomatic infection

Potential mRNA vaccines for influenza

Potential mRNA vaccines for influenza

High-dose Vitamin B6 tablets could reduce feelings of anxiety and depression

High-dose Vitamin B6 tablets could reduce feelings of anxiety and depression

Novel nanoligomer approach to treat severe COVID-19

Novel nanoligomer approach to treat severe COVID-19

The potential of circular RNA COVID-19 vaccines

The potential of circular RNA COVID-19 vaccines

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.